---
document_datetime: 2023-09-21 17:47:06
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/refludan-epar-procedural-steps-taken-authorisation_en.pdf
document_name: refludan-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5315958
conversion_datetime: 2025-12-19 01:02:31.421877
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant  BEHRINGWERKE AG, Germany submitted on 20 December 1995 to the European Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA),  an  application  to  obtain  Marketing Authorisation for the medicinal product Refludan in accordance with the Centralised Procedure falling within the scope of Part A of the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993.

## Licensing/authorisation status:

The product is not licensed in any country outside the EU.

The Rapporteur and the two Co-Rapporteurs appointed by the CPMP  were: Rapporteur: Dr. P. Sjoberg Assessors: Dr. A. Johnsson Dr. U. Hammerling Dr. J.R. Wade Dr. P. Nilsson Co-Rapporteur: Dr. D. Jefferys Assessors: Mrs. M. Dow Dr. G. Turnbull Prof. J. Lewis Dr. F. Rotblat 2. Steps taken for the assessment of the product · The Rapporteur's initial assessment report was circulated to all CPMP members on 11 March 1996. · The Co-Rapporteur initial assessment report was circulated to all CPMP members on 11 March 1996. · In  their  March  meeting,  the  CPMP  agreed  the  need  of  performing  a  inspection  of  the  active substance manufacturing site 'Roussel Uclaf', Roumanville, France. · During the May CPMP meeting, a break out session took place for the preparation of the draft CPMP list of questions. · The CPMP agreed on the consolidated list of questions to be sent to the applicant on 22 May 1996. Medicinal product no longer authorised

- The Inspection performed of the active substance manufacturing by the Agence du Medicament in  the  Roussel  Uclaf  manufacturing  plant  (chemical  division,  Roumanville,  France)  was concluded to be satisfactory on 24 July 1996.
- The applicant submitted the responses to the CPMP consolidated list of questions on 6 September 1996.
- The Rapporteur's assessment report of the responses to the consolidated list of questions was circulated to all CPMP members on 7 October 1996.
- The update overall Rapporteurs's assesment report on the outstanding issues was circulated to all CPMP members on 11 November 1996.

<div style=\"page-break-after: always\"></div>

- Undertaking on the follow up measures issued by the Company was circulated on 19 November 1996.
- The CPMP in their meeting on 18-21 November 1996, on the basis of the favorable benefit-risk assessment, issued a positive opinion for granting a marketing authorisation to Refludan.
- The  CPMP  opinion  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission which adopted the corresponding Decisions on 13 March 1997.

<!-- image -->